Narain Morgan, Breen Miyuki, Carll Alex P, Hazari Mehdi, Farraj Aimen, Ward-Caviness Cavin K
Curriculum in Toxicology and Environmental Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC, USA.
Center for Public Health and Environmental Assessment, US Environmental Protection Agency, 104 Mason Farm Rd, Chapel Hill, NC, 27510, USA.
Environ Health. 2025 Aug 7;24(1):55. doi: 10.1186/s12940-025-01203-5.
Fine particulate matter (PM) is associated with cardiovascular morbidity, especially among individuals with pre-existing cardiovascular conditions, such as heart failure (HF). Medical management with β-blockers may modify the association between PM and heart rate (HR) as β-blockers act on similar neurophysiologic pathways as PM.
To examine potential medication-PM interactions, we utilized electronic health records (EHRs) from 26,653 individuals with HF in North Carolina observed from 2014 to 2016. Linear mixed effect models with a random intercept for individual were adjusted for individual and census level demographics and socioeconomic confounders. We examined 0-4-daily PM lags as well as the 5-day moving average. We stratified observations based β-blocker prescription status and quantified differences using a multiplicative interaction model. We also utilized data from an in vivo study of diesel exhaust exposure and β-blocker usage in HF prone rats to validate results and examine additional outcomes unavailable in the EHR data.
Stratified analyses and the multiplicative interaction model revealed a significant difference in the association between PM and HR based on β-blocker prescription status. For 5-day average PM we observed a significant interaction (β = -0.68, 95% CI: -0.82, -0.55) indicating that the association between PM and HR decreased for observations occurring after prescription of a β-blocker to study participants. This observation was reflected in the in vivo study as well.
β-blocker usage likely attenuates associations between short-term PM and HR. Accounting for this in future studies may reveal novel means of reducing PM-related cardiovascular morbidity and reduce confounding in population with high rates of β-blocker usage.
细颗粒物(PM)与心血管疾病发病率相关,尤其是在已有心血管疾病的个体中,如心力衰竭(HF)患者。使用β受体阻滞剂进行药物治疗可能会改变PM与心率(HR)之间的关联,因为β受体阻滞剂与PM作用于相似的神经生理途径。
为了研究潜在的药物 - PM相互作用,我们利用了2014年至2016年在北卡罗来纳州观察到的26653例HF患者的电子健康记录(EHR)。对个体具有随机截距的线性混合效应模型针对个体和人口普查水平的人口统计学及社会经济混杂因素进行了调整。我们研究了0 - 4天的每日PM滞后以及5天移动平均值。我们根据β受体阻滞剂的处方状态对观察结果进行分层,并使用乘法相互作用模型量化差异。我们还利用了一项关于易患HF大鼠的柴油废气暴露和β受体阻滞剂使用的体内研究数据来验证结果,并检查EHR数据中无法获得的其他结局。
分层分析和乘法相互作用模型显示,基于β受体阻滞剂处方状态,PM与HR之间的关联存在显著差异。对于5天平均PM,我们观察到显著的相互作用(β = -0.68,95% CI:-0.82,-0.55),表明在向研究参与者开具β受体阻滞剂处方后出现的观察结果中,PM与HR之间的关联降低。这一观察结果在体内研究中也得到了体现。
使用β受体阻滞剂可能会减弱短期PM与HR之间的关联。在未来的研究中考虑这一点可能会揭示降低PM相关心血管疾病发病率的新方法,并减少β受体阻滞剂高使用率人群中的混杂因素。